机构观点 证券之星2026年2月10日发布的估值分析显示，中源协和相对估值区间为21.33-23.58元，估值准确性评 级为C，表明当前股价偏高。基本面方面，公司行业内护城河一般，2025年前三季度营收10.92亿元，净 利润1.08亿元，盈利能力承压。机构舆情偏中性，市盈率(TTM)达161.33倍，反映市场对干细胞长期政 策红利的预期。 经济观察网近期中源协和股价呈现小幅波动。截至2026年2月11日，最新股价为25.77元，近5日累计上 涨1.70%，但20日跌幅为-6.36%。成交活跃度较低，2月11日换手率仅0.60%，日均成交额约1.2亿元。同 期医药生物板块下跌0.32%，公司股价表现略优于行业。 财报分析 2025年三季报数据显示，公司营收与利润同比双降，但第三季度单季营收降幅收窄至6.82%，归母净利 润微增3.74%，经营状况呈现边际改善。毛利率维持在69.22%的高位，经营活动现金流净额2.23亿元， 主业造血能力稳定。 以上内容基于公开资料整理，不构成投资建议。 ...

2月11日，健康160(02656)股价在低开震荡约1个小时后突然大幅跳水，半个小时内，公司股价从约90港元跳水跌至最 低55港元，盘中股价振幅接近40%，最终公司当日收跌30.73%。公司股价由此回吐年内多数涨幅，总市值一度跌穿 200亿港元。 从发行方案来看，华芢生物在发行上采用了"机制B+无基石"方式，倚赖机构投资者作"市场锚定"。如今看来，该方案 对于一家基本面有待提高的未盈利18A而言或许有些激进，但对于当时的华芢生物来说，只是"踩着石头过河"，而这 条路正是健康160踩出来的。 靠"机制B+无基石"博进港股通 其实对比华芢生物和健康160的IPO发行方案，投资者不难看出二者间的相似之处。 自去年8月港交所港股发布IPO新规以来，不少企业把公开配售压到10%的下限，"人为制造"极致缩量的流通盘，并形 成以机构、基石和锚定投资者为主的发行格局，为公司上市开局"保价护航"。据智通财经APP了解，在选择"机制B"的 基础上，两家公司均选择了"无基石"方案，仅设有"绿鞋"机制。如此一来，其高达90%的国际配售比例在缺乏基石锁 仓情况下，基本只能倚赖机构投资者作"市场锚定"。 根据发行计划，健康160全球发售 ...

Core Viewpoint - The "Three-Year Action Plan for Supporting the Transformation and Upgrading of Advanced Manufacturing Industry in Shanghai (2026-2028)" aims to accelerate the establishment of a modern industrial system centered on advanced manufacturing, promoting green and digital transformation across enterprises of all sizes [1][2]. Group 1: Action Plan Overview - The action plan includes four major actions and 17 measures to enhance the development of advanced manufacturing in Shanghai [1]. - By 2028, Shanghai aims to add 100 manufacturing enterprises with an annual output value exceeding 1 billion yuan and increase the number of industrial enterprises above designated size by 500 [1]. Group 2: Development Paths - The plan outlines three development paths: - For traditional advantageous industries, it emphasizes "optimization and enhancement" [1]. - For leading industries, it promotes "strategic guidance" [1]. - For key and emerging industries, it focuses on "expansion and development" [1]. Group 3: Innovation and Support Measures - The action plan supports enterprises in high-level R&D and high-value product transformation, addressing industry pain points and overcoming key core technologies [2]. - Financial support includes one-time subsidies for R&D investments, with amounts varying based on the level of investment [2]. Group 4: Financial Incentives - Companies investing in technology transformation projects can receive interest subsidies on loans or equipment financing leases, with a maximum subsidy of 20 million yuan [3]. - Additional rewards are available for energy-saving upgrades and for companies recognized as national green factories [3].

2025年济南各区县GDP成绩单近日正式出炉。据济南市统计局网站数据，东部地区（历下、高新、历 城、章丘、莱芜、钢城）加起来的GDP已达到9193.9亿元，占济南全市GDP总值的64.7%。 其中，主城区四区（历下、高新、历城、章丘）合计GDP 7777.2亿，增速普遍跑赢全市5.4%的均线， 高新7.61%、章丘5.9%、历下5.6%，历城区增速略低，为5.1%，整体表现稳健可观，"东强"战略正在成 为加速兑现的现实。 相较于起步区10.4%的增速，这个增速显然不那么亮眼，但是，在四区如此庞大的经济体量下，能够实 现这样的增长，难度远超中小体量区域的快速攀升。大象起舞，从来比兔子奔跑更难。 东部何以跑出这样的成绩？ 第一， 齐鲁科创大走廊的轴线效应。从高新区中心区到章丘明水，济南市以经十东路和旅游路为主 体，沿线布局了产研院、超算中心、中科院科创城、山大龙山校区等一批重量级科研平台，形成了一条 绵延数十公里的创新带。科研成果在走廊的一端诞生，在另一端的智能智造走廊完成产业化落地。这 条"研发—中试—量产"的通道，是东部产业能级持续跃升的底层逻辑。 第二，国家级开发区的载体优势。济南高新区和章丘明水经济技术开 ...

长效生物制剂龙头特宝生物(688278.SH)经营业绩再现稳健增长。 2月10日晚，特宝生物披露了2025年业绩快报。当年，公司实现的营业收入、归母净利润分别为36.96亿 元、10.38亿元，同比增速均超过20%，均创下历史新高。 特宝生物解释，公司重点产品销售收入稳定增长，新产品获批上市带来销售收入新增长点。 长江商报记者发现，2018年至2025年的八个年度，特宝生物的营收净利实现了连续八年增长。 与业绩增长相关联的是，特宝生物的经营现金流持续净流入。2025年前三季度，公司经营现金流净额为 4.71亿元，同比增长61.33%。 特宝生物重点聚焦乙肝临床治愈领域，截至2025年6月末，公司已经上市六个药品及一款电子笔式注射 器。 特宝生物的研发投入持续增加，2025年前三季度，公司研发投入为3.12亿元，同比增长38.67%。 特宝生物持续回报股东。2020年上市以来，公司已经连续五年分红，合计分红5.67亿元，为股权融资额 的1.5倍。 年度盈利首次突破10亿大关 特宝生物业绩延续双增的良好发展势头。 根据最新发布的业绩快报，2025年，特宝生物实现营业收入36.96亿元，同比增长31.18%；归母净 ...

Core Insights - The provincial strategic emerging industry fund cluster held its first meeting of 2026, signing agreements for five specialized funds with a total scale of 69.1 billion yuan, raising the total scale of the fund cluster to 275.6 billion yuan [1][2] Group 1: Fund Details - The Long Triangle Venture Capital Guidance Fund, with a scale of 55.1 billion yuan, is a key highlight of the signing, aimed at supporting the integration development strategy of the Yangtze River Delta region [1] - The provincial fund for high-quality development of new industries, initiated by the High Investment Group, has a scale of 10 billion yuan and focuses on sectors such as biomedicine, new energy, integrated circuits, artificial intelligence, and robotics [1] - The Jiangsu Province Suhao Modern Service Industry Innovation Development Fund aims to promote the deep integration of modern service industries with strategic emerging industries, with a target scale of 10 billion yuan and an initial phase of 2 billion yuan [1] Group 2: Fund Cluster Achievements - The provincial strategic emerging industry fund cluster has established a total of 46 specialized funds with a cumulative scale of 176 billion yuan, completing decision-making processes for 50 sub-funds totaling 49.6 billion yuan [2] - The fund cluster has invested in over 200 projects, leading to direct equity investments exceeding 20 billion yuan, with two direct investment projects achieving IPO listings [2]

Core Insights - Singapore attracted 14.2 billion SGD in fixed asset investments in 2025, marking a 5.2% year-on-year increase despite global geopolitical and economic challenges [1] - Chinese investments surged, increasing from 2.5% in 2024 to 20.6% in 2025, surpassing the US to become Singapore's second-largest investment source after Europe [1] Investment Structure - Of the 14.2 billion SGD in fixed asset investment commitments, approximately 12.1 billion SGD came from manufacturing-related projects, accounting for 85% [2] - Semiconductor manufacturing led the investments, contributing 33% of the fixed asset investments, driven by the explosive growth in global AI demand [2] - Investments in biopharmaceutical manufacturing, specialty chemicals, sustainable materials, and aerospace maintenance also saw significant interest from Chinese enterprises [2] Strategic Shifts in Operations - 55% of surveyed Chinese enterprises rated Singapore's business environment as "excellent," with public services and financial systems being key attractions [3] - The strategic positioning of Chinese enterprises in Singapore has evolved from a "springboard" to a "regional headquarters hub," with over 70% viewing the Johor-Singapore Economic Zone as vital for capacity expansion and cost management [3] Full Industry Chain Ecosystem - Chinese companies are establishing a comprehensive industry chain ecosystem in Singapore, with firms like ByteDance and Ant Group setting up regional headquarters [4] - This integrated model of "R&D + manufacturing + sales + financial management" signifies a shift from simple market expansion to global value chain restructuring [4] - Singapore's role as an international financial center facilitates comprehensive financial services for Chinese enterprises, reducing reliance on the US dollar system [4] Regional Economic Integration - The influx of Chinese investments in Singapore reflects the accelerating economic integration between China and Southeast Asia [5] - The model of "Singapore base + ASEAN manufacturing + global sales" is being replicated in countries like Vietnam and Malaysia, reshaping the global supply chain geography [5] Future Outlook - The investment trend from Chinese enterprises in Singapore is expected to continue, driven by factors such as the advancement of the China-Singapore Free Trade Agreement and Singapore's role in digital currency trials [6] - Despite potential challenges, the Singapore model remains a preferred strategy for Chinese enterprises to navigate trade barriers and expand into global markets [6]

Core Viewpoint - Shenzhen aims to enhance its modern industrial system by implementing the "20+8" strategic emerging industry cluster and future industry policy system 3.0 by 2026, targeting a growth of over 7% in the added value of strategic emerging industries [1] Group 1: Strategic Emerging Industries - By 2025, the added value of Shenzhen's strategic emerging industries is projected to reach 1.67 trillion yuan, accounting for 43% of the regional GDP, with 1,333 national-level specialized and innovative "little giant" enterprises [1] - Shenzhen will focus on enhancing the development capabilities of key industries such as new generation electronic information, new energy vehicles, and semiconductors, while accelerating the construction of major integrated circuit manufacturing projects [2] - The city plans to expand its low-altitude economy, biomedicine, and high-performance materials sectors, promoting deep collaboration in manufacturing and service support [2] Group 2: Innovation and Talent Attraction - Shenzhen will accelerate the construction of key research projects in various fields, including integrated circuits and advanced materials, with over 150 major R&D projects planned [3] - The city aims to increase R&D investment by over 10% this year and attract high-level talent in key technology sectors through initiatives like the "Million Talents Gathering" plan [3] - Shenzhen plans to establish a robust ecosystem of over 10,000 innovation and investment funds, supporting high-growth enterprises [3] Group 3: Urban Development and Infrastructure - Shenzhen will develop new urban areas with a focus on integrating education, research, and finance, while enhancing infrastructure such as the extension of Metro Line 13 [4] - The city aims to become a global leader in smart city development, with plans to add 2,000 5G-A base stations and improve IoT sensing platforms [4] Group 4: Consumer Market and Economic Growth - Expanding domestic demand and promoting consumption will be a priority for Shenzhen in 2026, with initiatives to foster new consumption growth points in AI and other sectors [6] - The city plans to develop world-class commercial districts and enhance the retail environment, including the addition of over 500 duty-free shops [7] - Shenzhen's retail sales are expected to stabilize at over 1 trillion yuan during the "14th Five-Year Plan" period, with significant growth in the wholesale and retail sectors [7] Group 5: Tourism and Cultural Development - Shenzhen aims to become a world-class tourist destination by developing various attractions and enhancing the overall tourism experience [5][6] - The city will focus on integrating sports and technology to create immersive consumer experiences in the sports sector [5] - Recommendations include improving the accommodation ecosystem to meet diverse consumer needs, enhancing the overall tourism infrastructure [8]

经济观察网Advanced Biomed Inc.近期有重大资产出售动作，股价波动显著，公司基本面仍处于未产生 收入且亏损的状态。 股票近期走势 该股在2025年12月至2026年1月初表现出较高的波动性。例如，在2025年12月26日股价下跌11.44%，而 在2026年1月5日又反弹上涨5.26%。这种波动可能反映了市场对上述公司动作的反应及整体交投情绪。 业绩经营情况 根据最新披露的财报数据，公司营业收入为0美元，净利润为-12,925.94美元，每股收益为0美元，市盈 率为负值(-1.89倍至-2.14倍)，显示公司仍处于未产生收入且亏损的状态。 机构观点 截至2026年1月8日，公开信息显示暂无机构对该股发布投资评级建议。 以上内容基于公开资料整理，不构成投资建议。 近期事件 公司在2025年12月23日签署协议，以23,000美元的总对价出售其全资香港子公司Advanced Biomed(HK)Limited的100%股权，包括该子公司拥有的所有知识产权。公司CEO表示此次出售是战略调 整的一部分，旨在应对中国监管环境的变化，未来临床试验将集中于台湾子公司进行。 ...

Core Viewpoint - The South Korean Ministry of Finance and Economy is focusing on expanding the export scale of the bio-health industry, including pharmaceuticals, medical devices, and cosmetics, through a "one-stop export" support initiative [1] Group 1: Export Support Initiatives - The "One-Stop Export 119" meeting was held to assist companies in overcoming export rule restrictions and operational difficulties caused by external environmental changes [1] - The government aims to create customized support plans and promote institutional reforms to enhance the export capabilities of the bio-health sector [1] Group 2: Industry Performance - In the previous year, South Korea's bio-health industry achieved a record export value of $27.9 billion [1] - The government is targeting to set new export records by 2026, indicating a strong growth trajectory for the industry [1]